HeartFlow has delivered a strong share price run in 2026, and with so much of the story tied to expectations for its medical imaging platform, the live question is whether the current valuation is supported by its sales. HeartFlow stock has also been in the headlines after fresh clinical data on its technology, which gives investors more to weigh when assessing what they are paying for each dollar of revenue.

• HeartFlow is up 88.1% year to date, which puts real pressure on the numbers to show that the business can grow into the higher market value implied by that move.

• New registry results presented at the 2026 American Heart Association conference suggest HeartFlow’s plaque analysis and CT guided PCI tools…